Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Case Studies: Success Stories from Biotech Consultancy Services

May 11, 2026

Transforming Research into Impactful Solutions

Biotech consultancy services play a pivotal role in transforming innovative research into impactful real-world solutions. By bridging the gap between scientific discovery and market implementation, these services help biotech companies navigate complex challenges and achieve their goals. Let's explore some success stories that highlight the significant impact of biotech consultancy services.

biotech laboratory

Streamlining Clinical Trials

One of the most critical phases in biotech development is clinical trials. A leading biotech company partnered with a consultancy to streamline their clinical trials process. The consultancy implemented a robust project management system, reducing trial timelines by 30%. This efficiency enabled the company to bring their groundbreaking treatment to market faster, ultimately benefiting patients worldwide.

The consultancy's expertise in regulatory compliance and data management was instrumental in achieving these results. By ensuring adherence to stringent regulations, the company avoided costly delays, demonstrating the value of specialized consultancy services in the biotech sector.

Enhancing Product Development

Another success story involves a startup focused on developing a novel therapeutic solution. Facing challenges in product development, they sought the expertise of a biotech consultancy. The consultancy provided strategic guidance, helping the startup refine their product design and optimize manufacturing processes.

product development meeting

Thanks to this collaboration, the startup successfully overcame technical hurdles and achieved a 50% increase in production efficiency. This improvement not only reduced costs but also accelerated time-to-market, highlighting the transformative impact of consultancy services on product development.

Navigating Regulatory Landscapes

Regulatory approval is often a daunting task for biotech companies. A mid-sized firm faced hurdles in obtaining approval for their innovative medical device. By working with a consultancy, they gained critical insights into the regulatory landscape and developed a comprehensive submission strategy.

The consultancy's in-depth knowledge of regulatory requirements enabled the firm to secure approval within a year, a process that typically takes much longer. This success underscores the consultancy's role in navigating complex regulatory environments, ensuring that companies can focus on innovation and growth.

regulatory strategy meeting

Driving Global Expansion

Global expansion presents both opportunities and challenges for biotech companies. A prominent biotech firm aiming to enter new markets enlisted the help of a consultancy to devise an effective expansion strategy. The consultancy conducted market research, identified key opportunities, and developed a tailored approach for each target market.

The result was a successful entry into three international markets within two years, significantly boosting the company's revenue and market presence. This case highlights how consultancy services can provide the strategic insights needed for successful global expansion.

Conclusion: The Value of Biotech Consultancy

These success stories demonstrate the crucial role that biotech consultancy services play in enabling companies to overcome challenges, streamline processes, and achieve remarkable success. By leveraging specialized expertise, companies can navigate the complexities of the biotech industry, transforming innovative ideas into impactful solutions that improve lives worldwide.